Skip to main content

Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.

Publication ,  Journal Article
Pae, C-U; Marks, DM; Masand, PS; Peindl, K; Hooper-Wood, C; Han, C; Mannelli, P; Ciccone, P; Patkar, AA
Published in: Clin Neuropharmacol
2009

There are limited data to indicate effective treatment strategies for antidepressant-related sexual dysfunction, in particular for patients with treatment-resistant major depression. We subanalyzed our published data whether augmentation with methylphenidate extended release (OROS MPH) improved sexual dysfunction associated with antidepressants in patients with treatment-resistant major depression. The primary efficacy measure was the change in Arizona Sexual Experiences Survey (ASEX) from baseline to end of treatment in an intent-to-treat analysis with last observation carried forward approach. There were no significant differences between the 2 groups in terms of changes in ASEX scores over time (F1,35 = 1.14; P = 0.32), although the numerical decrease in ASEX score was greater in OROS MPH (mean change, -4.5; 20.1% decrease) than in the placebo group (mean change, -0.6; 2.6% decrease). Augmentation with OROS MPH showed no statistically significant benefit in antidepressant-related sexual dysfunction, although addition of OROS MPH to antidepressants did not worsen preexisting sexual dysfunction. Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Neuropharmacol

DOI

EISSN

1537-162X

Publication Date

2009

Volume

32

Issue

2

Start / End Page

85 / 88

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Surveys and Questionnaires
  • Sexual Dysfunction, Physiological
  • Severity of Illness Index
  • Psychiatric Status Rating Scales
  • Neurology & Neurosurgery
  • Middle Aged
  • Methylphenidate
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pae, C.-U., Marks, D. M., Masand, P. S., Peindl, K., Hooper-Wood, C., Han, C., … Patkar, A. A. (2009). Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. Clin Neuropharmacol, 32(2), 85–88. https://doi.org/10.1097/WNF.0b013e31817e559b
Pae, Chi-Un, David M. Marks, Prakash S. Masand, Kathleen Peindl, Christa Hooper-Wood, Changsu Han, Paolo Mannelli, Patrick Ciccone, and Ashwin A. Patkar. “Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.Clin Neuropharmacol 32, no. 2 (2009): 85–88. https://doi.org/10.1097/WNF.0b013e31817e559b.

Published In

Clin Neuropharmacol

DOI

EISSN

1537-162X

Publication Date

2009

Volume

32

Issue

2

Start / End Page

85 / 88

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Surveys and Questionnaires
  • Sexual Dysfunction, Physiological
  • Severity of Illness Index
  • Psychiatric Status Rating Scales
  • Neurology & Neurosurgery
  • Middle Aged
  • Methylphenidate
  • Male
  • Humans